# Vyndaqel

NDC: 0069-1975
Generic name: tafamidis meglumine
Labeler / Manufacturer: Pfizer Laboratories Div Pfizer Inc
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: CAPSULE, LIQUID FILLED
Routes: ORAL
Marketing started: 20190516
Marketing ended: 20270731
FDA application: NDA211996

## Active ingredients

- TAFAMIDIS MEGLUMINE: 20 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0069-1975"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0069-1975
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b4121ee-a733-4456-a917-be2603477839